Treatment preferences in human papillomavirus-associated oropharyngeal cancer

Melina J. Windon, Gypsyamber D'Souza, Carole Fakhry

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


The population of survivors with human papillomavirus-associated oropharyngeal squamous cell carcinoma (HPV-OPSCC) is rising. The improved prognosis of this etiologic subset is reflected in new staging guidelines as well as ongoing deintensification trials aiming to preserve excellent survival while decreasing treatment-related toxicities. However, as staging criteria and treatment standards evolve in the era of transoral surgery and deintensification, little is known regarding the needs and treatment preferences of patients with HPV-OPSCC. Herein, the current knowledge regarding treatment preferences and priorities, quality of life and concerns among patients with HPV-OPSCC is reviewed.

Original languageEnglish
Pages (from-to)2521-2530
Number of pages10
JournalFuture Oncology
Issue number24
StatePublished - Oct 2018

Bibliographical note

Publisher Copyright:
© 2018 Future Medicine Ltd.


  • Head and neck cancer
  • Human papillomavirus
  • Oropharyngeal cancer
  • Otolaryngology
  • Patient preference
  • Radiotherapy
  • Robotic surgical procedures
  • Shared decision-making

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Treatment preferences in human papillomavirus-associated oropharyngeal cancer'. Together they form a unique fingerprint.

Cite this